XML 66 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2022
Nonvested Restricted Shares

A summary of the Company’s nonvested restricted shares as of December 31, 2022 and 2021, and changes during the years then ended is presented below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Average

 

 

 

 

 

Average

 

 

 

 

 

 

Grant Date

 

 

 

 

 

Grant Date

 

 

 

 

 

 

Fair Value

 

 

 

 

 

Fair Value

 

 

 

Shares

 

 

(per share)

 

 

Shares

 

 

(per share)

 

Nonvested at the beginning of the year

 

 

491,239

 

 

$

3.50

 

 

 

849,723

 

 

$

2.86

 

Granted

 

 

386,908

 

 

 

3.93

 

 

 

213,465

 

 

 

4.23

 

Vested

 

 

(113,886

)

 

 

6.16

 

 

 

(311,128

)

 

 

2.26

 

Forfeited

 

 

(74,399

)

 

 

4.44

 

 

 

(260,821

)

 

 

3.49

 

Nonvested at the end of the year

 

 

689,862

 

 

$

3.20

 

 

 

491,239

 

 

$

3.50

 

Expected to vest

 

 

689,862

 

 

$

3.20

 

 

 

491,239

 

 

$

3.50

 

 

 

 

Time-Vested Stock Options [Member]  
Valuation Assumptions, Options

Grant date fair values of time-vested stock option awards were estimated using the Black-Scholes option valuation model with the following assumptions:

 

 

 

 

 

 

 

 

 

 

Expected

 

Risk Free

 

Grant Date

 

 

 

 

 

 

 

Expected

 

Dividend

 

Interest

 

Fair Value

 

Grant Year

 

Grant Date

 

Expected Life

 

Volatility

 

Yield

 

Rate

 

Per Award

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2022

 

1/17/2022

 

6 years

 

74.32%

 

0.00%

 

1.60%

 

$

2.63

 

2022

 

2/4/2022

 

6 years

 

74.27%

 

0.00%

 

1.81%

 

$

2.30

 

2022

 

3/21/2022

 

6 years

 

74.45%

 

0.00%

 

2.33%

 

$

2.90

 

2022

 

4/19/2022

 

6 years

 

75.31%

 

0.00%

 

2.91%

 

$

3.87

 

2022

 

7/11/2022

 

6 years

 

77.95%

 

0.00%

 

3.04%

 

$

2.41

 

2022

 

7/18/2022

 

6 years

 

77.92%

 

0.00%

 

3.04%

 

$

2.51

 

2022

 

8/29/2022

 

6 years

 

78.17%

 

0.00%

 

3.24%

 

$

3.10

 

2022

 

9/6/2022

 

6 years

 

78.19%

 

0.00%

 

3.41%

 

$

2.81

 

2022

 

12/1/2022

 

6 years

 

78.20%

 

0.00%

 

3.65%

 

$

2.60

 

 

Option Activity

A summary of the Company’s time-vested stock options activity and related information at December 31, 2022 and 2021, and changes during the years then ended, is presented below:

 

 

 

 

 

 

December 31,

 

 

 

 

 

 

2022

 

 

2021

 

 

 

 

 

 

Weighted-

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Average

 

 

 

 

 

Average

 

 

 

 

 

 

Exercise

 

 

 

 

 

Exercise

 

 

 

Options

 

 

Price

 

 

Options

 

 

Price

 

 

 

Outstanding

 

 

(per share)

 

 

Outstanding

 

 

(per share)

 

Outstanding at the beginning of the year

 

 

733,967

 

 

$

5.66

 

 

 

211,361

 

 

$

11.68

 

Granted

 

 

513,518

 

 

 

3.95

 

 

 

608,485

 

 

 

4.04

 

Exercised

 

 

(102,850

)

 

 

3.98

 

 

 

-

 

 

 

-

 

Forfeited or expired

 

 

(255,821

)

 

 

4.76

 

 

 

(85,879

)

 

 

9.02

 

Outstanding at the end of the year

 

 

888,814

 

 

$

5.12

 

 

 

733,967

 

 

$

5.66

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at the end of the year

 

 

227,056

 

 

$

8.39

 

 

 

111,516

 

 

$

13.86

 

 

Shares Outstanding

A summary of the Company’s time vested stock options outstanding as of December 31, 2022 is presented below:

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Remaining

 

 

Average

 

 

 

 

 

 

 

 

 

Contractual

 

 

Exercise

 

 

Aggregate

 

 

 

Options

 

 

Term

 

 

Price

 

 

Intrinsic

 

 

 

Outstanding

 

 

(in years)

 

 

(per share)

 

 

Value

 

Options outstanding

 

 

888,814

 

 

 

8.3

 

 

$

5.12

 

 

$

-

 

Vested or expected to vest

 

 

888,814

 

 

 

8.3

 

 

$

5.12

 

 

$

-

 

Options exercisable

 

 

227,056

 

 

 

6.5

 

 

$

8.39

 

 

$

-

 

 

Stock Appreciation Rights (SARs) [Member]  
Shares Outstanding

A summary of the Company’s cash settled stock appreciation rights outstanding as of December 31, 2022 is presented below:

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Remaining

 

 

Average

 

 

 

 

 

 

 

 

 

Contractual

 

 

Exercise

 

 

Aggregate

 

 

 

SARS

 

 

Term

 

 

Price

 

 

Intrinsic

 

 

 

Outstanding

 

 

(in years)

 

 

(per share)

 

 

Value

 

SARS outstanding

 

 

2,132,113

 

 

 

7.8

 

 

$

2.20

 

 

$

2,124,866

 

Vested or expected to vest

 

 

2,132,113

 

 

 

7.8

 

 

$

2.20

 

 

$

2,124,866

 

SARS exercisable

 

 

909,313

 

 

 

7.7

 

 

$

2.10

 

 

$

997,916

 

 

Valuation Assumptions

The fair value of cash settled stock appreciation rights as of December 31, 2022 was estimated using the Black-Scholes option valuation model with the following assumptions:

 

 

 

 

 

 

 

 

 

Expected

 

Risk Free

 

 

 

 

 

 

 

 

 

Expected

 

Dividend

 

Interest

 

Fair Value

 

Grant Year

 

Grant Date

 

Expected Life

 

Volatility

 

Yield

 

Rate

 

Per Award

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2020

 

1/24/2020

 

3.6 years

 

94.35%

 

0.00%

 

4.19%

 

$

2.44

 

2020

 

9/14/2020

 

4.2 years

 

89.86%

 

0.00%

 

4.10%

 

$

2.38

 

2020

 

11/30/2020

 

4.4 years

 

87.88%

 

0.00%

 

4.07%

 

$

2.28

 

2021

 

1/5/2021

 

4.3 years

 

89.36%

 

0.00%

 

4.09%

 

$

2.31

 

 

SAR Activity

A summary of the Company’s cash settled stock appreciation rights activity and related information at December 31, 2022 and 2021 and changes during the year is presented below:

 

 

 

 

 

 

December 31,

 

 

 

 

 

 

2022

 

 

2021

 

 

 

 

 

 

Weighted-

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Average

 

 

 

 

 

Average

 

 

 

 

 

 

Exercise

 

 

 

 

 

Exercise

 

 

 

SARS

 

 

Price

 

 

SARS

 

 

Price

 

 

 

Outstanding

 

 

(per share)

 

 

Outstanding

 

 

(per share)

 

Outstanding at the beginning of the year

 

 

2,163,339

 

 

$

2.20

 

 

 

853,967

 

 

$

1.69

 

Granted

 

 

-

 

 

 

-

 

 

 

1,735,500

 

 

 

2.38

 

Exercised

 

 

(11,592

)

 

 

2.16

 

 

 

(42,652

)

 

 

1.64

 

Forfeited or expired

 

 

(19,634

)

 

 

2.31

 

 

 

(383,476

)

 

 

1.92

 

Outstanding at the end of the year

 

 

2,132,113

 

 

$

2.20

 

 

 

2,163,339

 

 

$

2.20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at the end of the year

 

 

909,313

 

 

$

2.10

 

 

 

192,387

 

 

$

1.71